SALARIUS PHARMACEUTICALS INC (SLRX)

US79400X3052 - Common Stock

0.485  -0.01 (-1.02%)

Premarket: 0.488 +0 (+0.62%)

News Image
2 days ago - Chartmill

These stocks have an unusual volume in today's session

Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.

News Image
3 days ago - BusinessInsider

Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket

Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today’s pre-market trading following fourth-quarter results.

News Image
3 days ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We are starting off the day with a breakdown of the biggest pre-market stock movers that traders need to know about on Monday morning.

News Image
5 days ago - InvestorPlace

SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023

SLRX stock results show that Salarius Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.

News Image
5 days ago - BusinessInsider

SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Salarius Pharmaceuticals (NASDAQ:SLRX) just reported results for the fourth qua...

News Image
6 days ago - Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic...

News Image
a month ago - Seeking Alpha

Salarius's CEO David Arthur steps down (NASDAQ:SLRX)

Salarius Pharmaceuticals announces cost-savings measures including CEO transition, reduced expenses, and compensation, to support ongoing clinical trials.

News Image
2 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time for a breakdown of the biggest pre-market stock movers for Wednesday morning as we check out all of the latest news today!

News Image
3 months ago - Salarius Pharmaceuticals, Inc.

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Additional Ewing Sarcoma Patient in Company’s Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients...

News Image
8 months ago - Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

FDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein degrader received Investigational New Drug...

News Image
9 months ago - Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

The trial will assess the safety and preliminary efficacy of Salarius’ novel targeted protein degrader SP-3164; Patient dosing expected to begin in 2H 2023...

News Image
10 months ago - Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care agent lenalidomide...

News Image
11 months ago - Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein...

News Image
a year ago - Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein...

News Image
a year ago - Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

FDA removes partial clinical hold on seclidemstat Phase 1/2 trial in Ewing sarcoma; Salarius plans to meet with FDA to discuss future development and...

News Image
a year ago - Salarius Pharmaceuticals, Inc.

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Decision Follows Review of Comprehensive Safety Data Package Submitted by the Company Salarius Plans to Meet with FDA to Discuss Future Development and...

News Image
a year ago - Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

Submission of Investigational New Drug application expected in the second quarter of 2023 with start of Phase 1 trial expected in second half of 2023...

News Image
a year ago - Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

SP-3164 demonstrates compelling antitumor activity in animal models of follicular lymphoma and compelling antitumor activity in animal models of multiple...

News Image
a year ago - Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

HOUSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein...

News Image
a year ago - Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Data to be presented at AACR demonstrate significant SP-3164 anticancer activity in both non-Hodgkin Lymphoma and Multiple Myeloma cell lines and animal...

News Image
a year ago - Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein...

News Image
a year ago - Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

HOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein...